Research Topics
| Garnet L AndersonSummaryAffiliation: Fred Hutchinson Cancer Research Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopauseRoss L Prentice
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Am J Epidemiol 170:12-23. 2009....- Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trialGarnet L Anderson
Fred Hutchinson Cancer Research Center, Public Health Sciences, Seattle, WA 98109, USA
Lancet Oncol 13:476-86. 2012..We aimed to assess the influence of oestrogen use on longer term breast cancer incidence and mortality in extended follow-up of this cohort... 
Obesity and the risk for premenopausal and postmenopausal breast cancerGarnet L Anderson
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, PO Box 19024, Seattle, WA 98109, USA
Cancer Prev Res (Phila) 5:515-21. 2012....
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trialGarnet L Anderson
Fred Hutchinson Cancer Research Center, Seattle, Wash 98109 1024, USA
JAMA 291:1701-12. 2004..Despite decades of use and considerable research, the role of estrogen alone in preventing chronic diseases in postmenopausal women remains uncertain...- Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trialsGarnet L Anderson
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Clin Trials 4:207-17. 2007..The results contravened prevailing wisdom and a large body of literature regarding benefits of menopausal hormone therapy. The results and their interpretation have been the subject of considerable debate... - Assessing lead time of selected ovarian cancer biomarkers: a nested case-control studyGarnet L Anderson
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, PO Box 19024, M3 A410, Seattle, WA 98109 1024, USA
J Natl Cancer Inst 102:26-38. 2010..Except for CA125, their behavior in the prediagnostic period has not been evaluated... - Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestinGarnet L Anderson
WHI Clinical Coordinating Center, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, M3 A410, P O Box 19024, Seattle, WA 98109 1024, United States
Maturitas 55:103-15. 2006..To assess the extent to which prior hormone therapy modifies the breast cancer risk found with estrogen plus progestin (E+P) in the Women's Health Initiative (WHI) randomized trial... - Implementation of the Women's Health Initiative study designGarnet L Anderson
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA
Ann Epidemiol 13:S5-17. 2003 - Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trialGarnet L Anderson
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Wash 98109, USA
JAMA 290:1739-48. 2003..The effects of continuous combined hormone therapy on gynecologic cancers have not been investigated previously in a randomized trial setting... - Estrogen plus progestin therapy and breast cancer in recently postmenopausal womenRoss L Prentice
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Am J Epidemiol 167:1207-16. 2008..64 (95% confidence interval: 1.00, 2.68) over a 5-year period of use and 2.19 (95% confidence interval: 1.56, 3.08) over a 10-year period of use... - Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational studyRoss L Prentice
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Am J Epidemiol 167:1407-15. 2008.... - Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled TrialRoss L Prentice
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, PO Box 19024, Seattle, WA 98109 1024, USA
J Natl Cancer Inst 99:1534-43. 2007..The trial protocol also listed ovarian cancer and endometrial cancer as outcomes that may be favorably affected by the intervention... - Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125Chirag A Shah
University of Washington, Seattle, WA 98195, USA
Cancer Epidemiol Biomarkers Prev 18:1365-72. 2009..To evaluate the effect of ovarian cancer risk on the performance of the serum biomarkers mesothelin, human epididymis protein 4 (HE4), and CA125... - Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification TrialRoss L Prentice
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Wash 98109, USA
JAMA 295:629-42. 2006..The hypothesis that a low-fat dietary pattern can reduce breast cancer risk has existed for decades but has never been tested in a controlled intervention trial... - Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification TrialShirley A A Beresford
Department of Epidemiology, University of Washington, Seattle, WA 98195 7236, USA
JAMA 295:643-54. 2006..Observational studies and polyp recurrence trials are not conclusive regarding the effects of a low-fat dietary pattern on risk of colorectal cancer, necessitating a primary prevention trial... - The women's health initiative: lessons learnedRoss L Prentice
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Annu Rev Public Health 29:131-50. 2008..A specimen repository and quality-controlled outcome data for a range of diseases are among the resources that support the ongoing research program. WHI clinical trial contributions and challenges are reviewed and discussed... - Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular diseaseRoss L Prentice
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Am J Epidemiol 163:589-99. 2006..An application to postmenopausal hormone treatment effects on coronary heart disease among younger women is also provided... - Effects of blood collection conditions on ovarian cancer serum markersJason D Thorpe
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
PLoS ONE 2:e1281. 2007..By measuring the effects of differences in collection conditions on three different markers, we investigated the potential of these effects to bias validation studies... - Potential role of HE4 in multimodal screening for epithelial ovarian cancerNicole Urban
Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
J Natl Cancer Inst 103:1630-4. 2011..03). Serum HE4 levels were found to increase with age and smoking status, suggesting that a longitudinal algorithm might improve its performance... - Comparing adaptive and non-adaptive algorithms for cancer early detection with novel biomarkersAlicia H Sato
Fred Hutchinson Cancer Research Center, Seattle, WA 90109, USA
Cancer Biomark 2:151-62. 2006.... - Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold ruleCharles W Drescher
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M2 B230, Seattle, WA 98104, USA
J Clin Oncol 31:387-92. 2013..We demonstrated improvement in ovarian cancer early detection by using a longitudinal algorithm to monitor annual CA125 levels... - Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohortsMarian L Neuhouser
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
Arch Intern Med 169:294-304. 2009..Therefore, we decided to examine associations between multivitamin use and risk of cancer, CVD, and mortality in postmenopausal women... - Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal womenClara Bodelon
Department of Epidemiology, School of Public Health, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Cancer Prev Res (Phila) 4:840-50. 2011..To provide more definitive evidence, a pooled analysis of all available studies or a much larger study would be needed... - Bead-based ELISA for validation of ovarian cancer early detection markersNathalie Scholler
Translational Outcomes Research Laboratory, Fred Hutchinson Cancer Research Center, Public Health Sciences, and Harborview Medical Center, University of Washington, Seattle, Washington, USA
Clin Cancer Res 12:2117-24. 2006.... - Long-term exposure to air pollution and incidence of cardiovascular events in womenKristin A Miller
Department of Epidemiology, University of Washington, Seattle, USA
N Engl J Med 356:447-58. 2007..We examined the association of long-term exposure to particulate matter of less than 2.5 microm in aerodynamic diameter (PM2.5) with cardiovascular events... - Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy useRowan T Chlebowski
Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502 2004, USA
Clin Breast Cancer 6:S58-64. 2006..If remaining issues are to be addressed, more rigorous CHD and stroke assessment procedures are needed in future trials evaluating AIs... - The Women's Health Initiative recruitment methods and resultsJennifer Hays
From the WHI Clinical Center, Baylor College of Medicine, Houston, TX 77030, USA
Ann Epidemiol 13:S18-77. 2003 - Ethnicity and breast cancer: factors influencing differences in incidence and outcomeRowan T Chlebowski
Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson St, Building J 3, Torrance, CA 90502, USA
J Natl Cancer Inst 97:439-48. 2005..The influence of breast cancer risk factors on these differences has received little attention... - Statistical issues arising in the Women's Health InitiativeRoss L Prentice
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Biometrics 61:899-911; discussion 911-41. 2005..This final topic seems important in resolving the discrepancy between WHI clinical trial and observational study results on postmenopausal hormone therapy and cardiovascular disease... - Ambient fine particulate matter exposure and myocardial ischemia in the Environmental Epidemiology of Arrhythmogenesis in the Women's Health Initiative (EEAWHI) studyZhu Ming Zhang
Epidemiologic Cardiology Research Center, Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, North Carolina 27104, USA
Environ Health Perspect 117:751-6. 2009..Ambient particulate matter (PM) air pollution is associated with coronary heart disease, but the pathways underlying the association remain to be elucidated... - Selecting differentially expressed genes from microarray experimentsMargaret Sullivan Pepe
Department of Biostatistics, University of Washington, Seattle, Washington 98195 7232, USA
Biometrics 59:133-42. 2003..Our approach leads naturally to a procedure for sample-size calculations, appropriate for exploratory studies that seek to identify differentially expressed genes... - Migraine history, nonsteroidal anti-inflammatory drug use, and risk of postmenopausal endometrial cancerAmanda I Phipps
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M4 B402, Seattle, WA 98109, USA
Horm Cancer 3:240-8. 2012..Similarly, current NSAID use was not associated with endometrial cancer risk (HR = 1.01, 95% CI = 0.88-1.16), regardless of BMI. Migraine history and NSAID use do not appear to be associated with risk of endometrial cancer... - Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomyMarcia L Stefanick
Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford, Calif 94305, USA
JAMA 295:1647-57. 2006..Preliminary results suggesting possible reduction in breast cancers warranted more detailed analysis... - Progestins and recurrence in breast cancer survivorsRowan T Chlebowski
J Natl Cancer Inst 97:471-2. 2005 - Projecting individualized absolute invasive breast cancer risk in African American womenMitchell H Gail
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Executive Plaza South Rm 8032, Bethesda, MD 20892 7244, USA
J Natl Cancer Inst 99:1782-92. 2007..We developed a model for projecting absolute risk of invasive breast cancer in African American women and compared its projections with those from the Breast Cancer Risk Assessment Tool... - Predicting risk of breast cancer in postmenopausal women by hormone receptor statusRowan T Chlebowski
Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 West Carson Street, Torrance, CA 90502, USA
J Natl Cancer Inst 99:1695-705. 2007..We evaluated and attempted to improve the performance of the Breast Cancer Risk Assessment Tool (i.e., the Gail model) for estimating invasive breast cancer risk by receptor status in postmenopausal women... - Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification TrialBarbara V Howard
MedStar Research Institute Howard University, Washington, DC, USA
JAMA 295:655-66. 2006..Multiple epidemiologic studies and some trials have linked diet with cardiovascular disease (CVD) prevention, but long-term intervention data are needed... - Calcium plus vitamin D supplementation and the risk of fracturesRebecca D Jackson
Division of Endocrinology, Ohio State University, 485 McCampbell, 1581 Dodd Dr, Columbus, OH 43210, USA
N Engl J Med 354:669-83. 2006..The efficacy of calcium with vitamin D supplementation for preventing hip and other fractures in healthy postmenopausal women remains equivocal... - Calcium plus vitamin D supplementation and the risk of colorectal cancerJean Wactawski-Wende
Department of Social and Preventive Medicine, University at Buffalo, 270 Farber Hall, Buffalo, NY 14214, USA
N Engl J Med 354:684-96. 2006..However, randomized-trial evidence that calcium with vitamin D supplementation is beneficial in the primary prevention of colorectal cancer is lacking... - Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestinGerardo Heiss
University of North Carolina, School of Public Health, Department of Epidemiology, Chapel Hill, NC 27514 3628, USA
JAMA 299:1036-45. 2008..The Women's Health Initiative (WHI) trial of estrogen plus progestin vs placebo was stopped early, after a mean 5.6 years of follow-up, because the overall health risks of hormone therapy exceeded its benefits... - Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal womenMarc J Gunter
Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York 10461, USA
Cancer Res 68:329-37. 2008.... - Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trialJacques E Rossouw
Division of Women s Health Initiative, National Heart, Lung, and Blood Institute, 6705 Rockledge Dr, One Rockledge Ctr, Suite 300, Bethesda, MD 20817
JAMA 288:321-33. 2002..Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain... - Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISANathalie Scholler
School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 96104 6069, USA
Clin Cancer Res 14:2647-55. 2008..Mouse monoclonal antibodies (mAb) and polyclonal antibodies (pAb) are commonly used, but because their production is lengthy and costly, recombinant antibodies are emerging as an attractive alternative... - Concerns about published data from the estrogen-progestin (HT) arm of the WHIMargery Gass
Am J Obstet Gynecol 192:333; author reply 334. 2005